Eagle Pharmaceuticals Inc (EGRX) Position Raised by Panagora Asset Management Inc.

Panagora Asset Management Inc. increased its position in shares of Eagle Pharmaceuticals Inc (NASDAQ:EGRX) by 41.8% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 59,120 shares of the specialty pharmaceutical company’s stock after purchasing an additional 17,441 shares during the quarter. Panagora Asset Management Inc. owned approximately 0.40% of Eagle Pharmaceuticals worth $4,099,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Great West Life Assurance Co. Can boosted its stake in shares of Eagle Pharmaceuticals by 31.0% in the 3rd quarter. Great West Life Assurance Co. Can now owns 13,948 shares of the specialty pharmaceutical company’s stock valued at $967,000 after purchasing an additional 3,300 shares during the last quarter. Carillon Tower Advisers Inc. bought a new position in shares of Eagle Pharmaceuticals in the 3rd quarter valued at about $2,946,000. Credit Suisse AG boosted its stake in shares of Eagle Pharmaceuticals by 11.9% in the 3rd quarter. Credit Suisse AG now owns 14,242 shares of the specialty pharmaceutical company’s stock valued at $987,000 after purchasing an additional 1,511 shares during the last quarter. Canada Pension Plan Investment Board boosted its stake in shares of Eagle Pharmaceuticals by 2,523.1% in the 3rd quarter. Canada Pension Plan Investment Board now owns 34,100 shares of the specialty pharmaceutical company’s stock valued at $2,364,000 after purchasing an additional 32,800 shares during the last quarter. Finally, Trexquant Investment LP bought a new position in shares of Eagle Pharmaceuticals in the 3rd quarter valued at about $243,000.

Several research analysts have recently issued reports on EGRX shares. Piper Jaffray Companies lowered shares of Eagle Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $82.00 to $54.00 in a research note on Wednesday, October 31st. Cantor Fitzgerald lowered shares of Eagle Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Thursday, November 1st. ValuEngine lowered shares of Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, October 31st. BidaskClub lowered shares of Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, September 18th. Finally, Royal Bank of Canada set a $64.00 price objective on shares of Eagle Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, November 2nd. Two analysts have rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $77.17.

Eagle Pharmaceuticals stock opened at $43.90 on Friday. Eagle Pharmaceuticals Inc has a fifty-two week low of $43.88 and a fifty-two week high of $85.66. The company has a market cap of $702.86 million, a P/E ratio of 22.55 and a beta of 1.71. The company has a debt-to-equity ratio of 0.20, a quick ratio of 5.38 and a current ratio of 5.59.

Eagle Pharmaceuticals (NASDAQ:EGRX) last released its quarterly earnings data on Thursday, November 1st. The specialty pharmaceutical company reported $1.18 earnings per share for the quarter, topping the consensus estimate of $0.91 by $0.27. Eagle Pharmaceuticals had a net margin of 13.92% and a return on equity of 17.62%. The business had revenue of $51.34 million for the quarter, compared to analyst estimates of $52.70 million. During the same quarter last year, the firm earned $1.22 EPS. Eagle Pharmaceuticals’s quarterly revenue was down 18.5% compared to the same quarter last year. Analysts expect that Eagle Pharmaceuticals Inc will post 2.03 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Eagle Pharmaceuticals Inc (EGRX) Position Raised by Panagora Asset Management Inc.” was first posted by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/12/08/eagle-pharmaceuticals-inc-egrx-position-raised-by-panagora-asset-management-inc.html.

Eagle Pharmaceuticals Profile

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).

Recommended Story: What is the float in trading stocks?

Want to see what other hedge funds are holding EGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eagle Pharmaceuticals Inc (NASDAQ:EGRX).

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply